CORRESP Filing
Entera Bio Ltd.
Date: June 4, 2025 · CIK: 0001638097 · Accession: 0001178913-25-002053
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287676
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jason Drory Registration Statement on Form S-3 (the “Registration Statement”) Filed May 30, 2025 File No. 333-287676
RE: Entera Bio Ltd. (the “Company”)
Dear Mr. Drory:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. on June 6, 2025, or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Entera Bio Ltd.
Show Raw Text
CORRESP 1 filename1.htm Entera Bio Ltd. Minrav Building – Fifth Floor Jerusalem, Israel 9112002 June 4, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jason Drory RE: Entera Bio Ltd. (the “Company”) Registration Statement on Form S-3 (the “Registration Statement”) Filed May 30, 2025 File No. 333-287676 Dear Mr. Drory: The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. on June 6, 2025, or as soon thereafter as practicable. [Signature page follows] Very truly yours, Entera Bio Ltd. By: /s/ Miranda Toledano Name: Miranda Toledano Title: Chief Executive Officer